

ANTI-DLL3 ANTIBODY AND METHOD OF MAKING AND USING THEREOF

FIGURES

FIG. 1




FIG. 1

FIG. 2




FIG. 2

FIG. 3




FIG. 3

FIG. 4




FIG. 4

FIG. 5




FIG. 5

FIG. 6

FIG. 6A

A. CHO-DLL3-EpCAM




FIG. 6

FIG. 6B

B. CORL-L279




FIG. 6

FIG. 6C

C. NCI-H82




FIG. 6

FIG. 6D

D. MIA Paca-2




FIG. 7

Antibody #1		Antibody #2				
Ab#	SI-83C1	SI-83C2	5029C10-FRS	5018A1-GS	5257C8-BSM	
SI-83C1	0	1.7506	1.5363	1.904	0.6013	
SI-83C2	1.7988	0	1.5289	2.0744	0.4651	
5029C10-FRS	1.9503	1.6854	0	1.8456	0.1325	
5018A1-GS	2.0603	1.5701	1.4278	0	0.4919	
5257C8-BSM	1.371	1.2232	0.9571	1.5422	0	

Self-Blocking Pairs
Blocking Pairs
Binding Pairs

FIG. 7




FIG. 8

FIG. 8

FIG. 9




FIG. 9




FIG. 10

A

	VH CDR1	VH CDR2	
SI-83M10 VH	QVQVLESGGGGLVQPGGSLALSCASGFDNMTYMTNVRQAPGKLEWVS	FIYASGGI-YS	59
SI-83M3 VH	K.....L...SNVFN	...AIA.G...-	59
5257C8-B3M VH	-Q..Q...R.IK..EP...I.KT..I.LSSK.PH	I..V...S...-	58
F2-AD005 VH	E...QQ..PE..K..A.VNI..HT..XT.TESS.H..K.SH..S...I..P.HNNL.GIS.		60
GenSun VH	E...L.....T.SS.G.H	A..GNN.SSK..	60
Gocetamig VH	E.....T.....SSVSLSLA.Y.....SR.L.AP.SDG.SI-V.		59
Chrintamig VH	Q..AEVNH..A.VNV..K...YT.TS..VH	Q...MYI.NSG...IS.	60
FT217 VH	E.R.SQ...QMKK..E.H...R...YT.IS.V.H	KRP..I..V.NFYDERTH.	60
Rovaipiturumab VH	Q..AEVVK..A.VNV..K...YT.TS.G.H	Q...M.V.NTYI.EPT.	60
Tarlatamab VH	Q...P...K.SEI.S.T.TV..GSISG..WS.I..P...C...I.VV.Y.T.-R.		59
	VH CDR2	VH CDR3	
SI-83M10 VH	KTRAKGFTISK--SRNTMVLQNSGLAKEDTAVVYCS	RIFFSGGIL-----KINQQGTLV	113
SI-83M3 VH	..K.....-I...V.....SK.G.IF-----L		111
5257C8-B3M VH	..S.....-I..VE...R...S.....GERSVA--YS-----N		110
F2-AD005 VH	QCKF...KA.LTVOK.SS.A.MELR..TS..S...QSS.YPD--YF-----Y...TL		114
GenSun VH	..DSV.....SDN...L.....DMPT--YLF-----Y		114
Gocetamig VH	MDSV.....RINKA..FY.....YKSWIT--RS-----FY		113
Chrintamig VH	..QNEL..V.MTERT.P..V.MELK...S.....GEAVT.MYFYVGH.V	T.	120
FT217 VH	..AKFQ..A.LISQYSD..AF.ELR...TSD.....RKY.VDG-----Y..R.AP.		114
Rovaipiturumab VH	..DDP...V.MTDT.IS.A.MELR...SC.....IGDS.PS-----Y		114
Tarlatamab VH	NPGL.S.V...VDI...QFS.KLS.VI.A.....SIAYIGFYF-----Y		114
SI-83M10 VH	IVYS		117
SI-83M3 VH			115
5257C8-B3M VH			114
F2-AD005 VH			113
GenSun VH			118
Gocetamig VH			117
Chrintamig VH			124
FT217 VH			118
Rovaipiturumab VH			118
Tarlatamab VH			118

B

	VL CDR1	VL CDR2	
SI-83M10 VL	DVMTQSGSSSVBASVGDRTITTCQSEETIS-----GNLA	FYQQKPGQAPKLLIYKASNLK	88
SI-83M3 VL	L.....S...QS-----SY.S	Q..I..	88
5257C8-B3M VL	..YQL.....ALT..Q...N...QR-----G..N.....R...K..	S...K..	88
F2-AD005 VL	NI.....E.M.M...E...LS.K...NV-----G-IVYS	D.S...S...RY	88
GenSun VL	..I.....L.LFVTP.EPAS.S.KS.QILLESQKTY..L..L...S.Q...EV..RA		60
Chrintamig VL	..IQ.....AM.....R..QG.....MY.V.F...K...R..AV.S.E		88
FT217 VL	EI.....GTL.L.P.E.A.LS.H..QN.H-----V..S.....R...K...E		88
Rovaipiturumab VL	EI.....ATLV.V.P.E.A.LS.K...QGV-----NENV	R...Z...RS	88
Tarlatamab VL	EI..L...GIL.L.P.E...LS.R...QVNN-----NY...R...R...K...SR.		86
	VL CDR2	VL CDR3	
SI-83M10 VL	GVPSGPFSGSGGGIDFILTISGLAFEDRTIYY	GSITFGISDVAAGGGGKVEIK---	110
SI-83M3 VL	E.....	QGVDSN.VEN.....	109
5257C8-B3M VL	S.....	QANSTANVDNI.....R.D.---	110
F2-AD005 VL	D..I...A.H.....V.A..L.S.H	PGSY---YFLI..A...L.L.RTY	110
GenSun VL	D.....K..AVEA..VGV...LQGE---RLPTT..Q.....RTV		115
Chrintamig VL	E.....	LGN---D.YFYI..Q...L.---	107
FT217 VL	E.I.D.....R.E...V...QSG---YFTT..Q.....		107
Rovaipiturumab VL	E.I.A.....E.....S...V...QGY---ISFNI..Q...L.---		107
Tarlatamab VL	E.I.D.....R.E...V...QY---DREFLI..C...L.---		108

FIG. 11

A

	CDRs Only									
	SI-83M10	SI-83M8	5257C8-BSM	FZ-AD005	GenSun	Gocetamig	Obixtamig	PT217	Rovalpituzumab	Tarlatamab
SI-83M10		41.0%	28.6%	28.6%	22.2%	13.0%	34.4%	36.7%	30.0%	32.3%
SI-83M8	41.0%		46.8%	29.3%	24.6%	25.0%	34.9%	35.6%	32.8%	25.4%
5257C8-BSM	46.8%	45.2%		24.1%	14.3%	56.7%	31.3%	37.9%	25.9%	36.1%
FZ-AD005	28.6%	29.3%	24.1%		28.6%	25.8%	35.9%	44.8%	43.1%	35.6%
GenSun	22.2%	24.6%	14.3%	28.6%		35.5%	31.9%	33.3%	33.3%	25.4%
Gocetamig	13.0%	25.0%	56.7%	25.8%	35.5%		5.6%	30.0%	25.9%	25.1%
Obixtamig	34.4%	34.9%	31.3%	35.9%	31.9%	5.6%		45.3%	32.3%	43.1%
PT217	36.7%	35.6%	37.9%	44.8%	33.3%	30.0%	45.3%		39.7%	33.3%
Rovalpituzumab	30.0%	32.8%	25.9%	43.1%	33.3%	25.8%	32.3%	39.7%		36.7%
Tarlatamab	32.3%	25.4%	36.1%	35.6%	25.4%	26.1%	43.1%	33.3%	36.7%	

FIG. 11

C

	VH+VL Regions									
	SI-83M10	SI-83M8	5257C8-BSM	FZ-AD005	GenSun	Gocetamig	Obixtamig	PT217	Revalpituzumab	Tariatamab
SI-83M10										
SI-83M8	67.8%	67.8%	81.1%	20.8%	53.0%	64.3%	62.8%	58.7%	58.7%	58.7%
5257C8-BSM	77.8%	71.8%	73.8%	53.7%	64.2%	63.2%	63.9%	59.9%	61.4%	61.0%
FZ-AD005	61.1%			50.7%	56.9%	51.7%	57.5%	54.2%	54.6%	58.3%
GenSun	70.8%	53.7%	50.7%		52.4%	40.7%	60.6%	60.9%	64.0%	53.7%
Gocetamig	53.0%	64.7%	56.9%	52.4%		70.3%	54.2%	58.3%	58.3%	58.3%
Obixtamig	64.3%	63.2%	51.7%	40.7%	78.3%		42.7%	39.0%	44.9%	47.5%
PT217	62.8%	59.9%	57.5%	60.6%	54.2%	42.7%		61.5%	68.6%	71.6%
Revalpituzumab	58.7%	61.4%	54.6%	64.0%	58.3%	39.0%	60.4%		66.4%	60.8%
Tariatamab	58.7%	61.0%	58.3%	53.7%	56.3%	47.5%	73.5%	60.8%		60.8%